---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-017298"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:39:27.713382+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma: ratutrelvir Phase 2 shows fewer AEs, faster symptom resolution; FDA hold on tivoxavir IND

## Summary
- Ratutrelvir Phase 2: 10% vs 23.3% adverse events, faster symptom resolution (HR 1.31, p=0.018), no viral rebound vs PAXLOVID.
- Ratutrelvir showed benefit in PAXLOVID-ineligible patients, addressing unmet need in high-risk COVID-19 population.
- Tivoxavir marboxil tablet formulation showed 30% increased pre-clinical exposure, modeled 28-day monthly prophylaxis.
- FDA placed US IND for tivoxavir marboxil on clinical hold due to mutagenicity concerns; formal communication by March 16, 2026.

## SEC filing metadata
- accession: 0001104659-26-017298
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465926017298/0001104659-26-017298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465926017298/tm266824d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-017298
- JSON: https://secwatch.observer/filing/0001104659-26-017298.json
- Plain text: https://secwatch.observer/filing/0001104659-26-017298.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.